Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating depemokimab as a treatment for adults aged 40 to 80 years with moderate to severe chronic obstructive pulmonary disease COPD characterized by type 2 inflammation and frequent exacerbations. This Phase 3 trial aims to assess the efficacy and safety of depemokimab when added to standard care compared to a placebo with standard care. The study is sponsored by GlaxoSmithKline and focuses on reducing the rate of moderate to severe COPD exacerbations. Participants will receive either subcutaneous injections of depemokimab or placebo alongside their optimized inhaler therapies, which include inhaled corticosteroids, long-acting muscarinic antagonists, and long-acting beta2-adrenergic agonists, all maintained for at least six months prior to the study. The study uses a randomized, double-blind, parallel-group design and lasts for up to 104 weeks, during which participants continue their standard care while receiving the study treatments. Throughout the study, participants will be regularly monitored for COPD exacerbations and changes in respiratory symptoms using validated tools like the St. Georges Respiratory Questionnaire and the Evaluating Respiratory Symptoms in COPD score. Researchers will also track emergency visits or hospitalizations related to exacerbations. Safety assessments and efficacy measurements will be collected throughout the two-year period to evaluate the impact of depemokimab as an add-on treatment.
Actively Recruiting
This research aims to evaluate the occurrence of blood clots, specifically thrombotic and thromboembolic events, in patients with congenital antithrombin deficiency who are undergoing surgery or childbirth. The study focuses on patients receiving Atenativ, an antithrombin concentrate, to understand its effects during these high-risk procedures. It is a Phase 3, open-label, uncontrolled study sponsored by Octapharma to assess efficacy, safety, and pharmacokinetics. Participants first enter a pharmacokinetic phase where they receive a single intravenous infusion of Atenativ at a dose of 60 IUkg to analyze how the drug behaves in the body. Following this, in the treatment phase, patients receive a single intravenous loading dose of Atenativ followed by maintenance doses every 24 hours. Surgical patients receive treatment for about 2 to 7 days, while pregnant participants receive treatment for approximately 5 days around the time of delivery or cesarean section. Throughout the study, participants will be monitored for blood clot events up to 30 days after starting treatment. Blood tests will measure various coagulation parameters and drug levels at multiple time points up to 14 days after the initial infusion. Safety and tolerability will also be assessed by tracking adverse events during this period. The total participation extends through the treatment and follow-up phases to ensure comprehensive evaluation of outcomes.